Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group-Reference-Cited by-同舟云学术

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Published:2015-01 Issue:1 Volume:45 Page:94-105
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Quach H.¹²,Joshua D.³⁴,Ho J.³⁴,Szer J.⁵,Spencer A.⁶,Harrison S. J.²⁷,Mollee P.⁸⁹,Roberts A. W.⁵,Horvath N.¹⁰,Talulikar D.¹¹¹²,To B.¹⁰,Zannettino A.¹⁰,Brown R.³,Catley L.⁹¹³¹⁴,Augustson B.¹⁵,Jaksic W.¹⁶,Gibson J.³⁴,Prince H. M.²⁷

Affiliation:

1. Department of Haematology; St Vincent's Hospital; Melbourne Victoria Australia

2. Faculty of Medicine, Dentistry and Health Sciences; University of Melbourne; Melbourne Victoria Australia

3. Department of Haematology; Royal Prince Alfred Hospital; Sydney New South Wales Australia

4. Faculty of Medicine; University of Sydney; Sydney New South Wales Australia

5. Department of Clinical Haematology and BMT; Royal Melbourne Hospital; Melbourne Victoria Australia

6. Department of Haematology; The Alfred Hospital; Melbourne Victoria Australia

7. Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Victoria Australia

8. Amyloidosis Centre and Department of Haematology; Princess Alexandra Hospital; Brisbane Queensland Australia

9. School of Medicine; University of Queensland; Brisbane Queensland Australia

10. Department of Haematology; South Australia Pathology; Adelaide South Australia Australia

11. Department of Haematology; Canberra Hospital; Canberra ACT Australia

12. Australian National University; Canberra ACT Australia

13. Department of Haematology; Mater Public Hospital; Brisbane Queensland Australia

14. Mater Medical Research Institute; Brisbane Queensland Australia

15. Department of Haematology; Sir Charles Gairdner Hospital; Perth Western Australia Australia

16. Department of Haematology; Queen Elizabeth Hospital; Adelaide South Australia Australia

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.12640/fullpdf

Reference76 articles.

1. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy;Levy;Medicine (Baltimore),2005

2. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma;Velde;Haematologica,2007

3. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials;Koreth;Biol Blood Marrow Transplant,2007

4. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation;Martinez-Lopez;Blood,2011

5. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma;Kyriakou;Br J Haematol,2005

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real‐world single‐centre experience;Internal Medicine Journal;2023-07-23

2. Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids;Value in Health;2023-01

3. Myeloma: Hiding in Plain Sight;Beyond Evidence-Based Medicine;2023

4. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR);Clinical Lymphoma Myeloma and Leukemia;2021-06

5. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR);Bone Marrow Transplantation;2021-05-19